Pediatric Neurology
Volume 38, Issue 3 , Pages 163-176 , March 2008

Fetal Mechanisms in Neurodevelopmental Disorders

  • Susan L. Connors, MD

      Affiliations

    • Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland
    • ,
  • Pat Levitt, PhD

      Affiliations

    • Vanderbilt Kennedy Center for Research on Human Development and Department of Pharmacology, Vanderbilt University, Nashville, Tennessee
    • ,
  • Stephen G. Matthews, PhD

      Affiliations

    • Departments of Physiology, Obstetrics and Gynecology, and Medicine, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Theodore A. Slotkin, PhD

      Affiliations

    • Department of Pharmacology and Cancer Biology, Duke University Medical Center, Durham, North Carolina
    • ,
  • Michael V. Johnston, MD

      Affiliations

    • Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland
    • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
    • ,
  • Hannah C. Kinney, MD

      Affiliations

    • Department of Pathology, Children’s Hospital Boston and Harvard Medical School, Boston, Massachusetts
    • ,
  • William G. Johnson, MD

      Affiliations

    • Department of Neurology, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, New Jersey
    • ,
  • Rosa M. Dailey, BA

      Affiliations

    • Fetal Physiology Foundation, Baltimore, Maryland
    • ,
  • Andrew W. Zimmerman, MD

      Affiliations

    • Department of Neurology and Developmental Medicine, Kennedy Krieger Institute, Baltimore, Maryland
    • Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland.
    • Corresponding Author InformationCommunications should be addressed to: Dr. Zimmerman; Department of Neurology and Developmental Medicine, Kennedy Krieger Institute; 707 North Broadway; Baltimore, MD 21205.

Received 30 August 2007 ,Accepted 29 October 2007.

References 

  1. Stahlberg O, Soderstrom H, Rastam M, Gillberg C. Bipolar disorder, schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or autism spectrum disorders. J Neural Transm. 2004;111:891–902
  2. Rakic P. Evolving concepts of cortical radial and areal specification. Prog Brain Res. 2002;136:265–280
  3. Levitt P, Rakic P. The time of genesis, embryonic origin and differentiation of the brainstem monoamine neurons in the rhesus monkey. Brain Res. 1982;256:35–37
  4. Paus T, Collins DL, Evans AC, Leonard G, Pike B, Zijdenbos A. Maturation of white matter in the human brain: A review of magnetic resonance studies. Brain Res Bull. 2001;54:255–266
  5. Bartzokis G, Beckson M, Lu PH, Nuechterlein KH, Edwards N, Mintz J. Age-related changes in frontal and temporal lobe volumes in men: A magnetic resonance imaging study. Arch Gen Psychiatry. 2001;58:461–465
  6. Bourgeois JP. Synaptogenesis, heterochrony and epigenesis in the mammalian neocortex. Acta Paediatr (Scand). 1997;422(Suppl):27–33
  7. Keller G, Zimmer G, Mall G, Amann K. Nephron number in patients with primary hypertension. N Engl J Med. 2003;348:101–108
  8. Stanwood GD, Levitt P. Drug exposure early in life: Functional repercussions of changing neuropharmacology during sensitive periods of brain development. Curr Opin Pharmacol. 2004;4:65–71
  9. Stanwood GD, Washington RA, Shumsky JS, Levitt P. Prenatal cocaine exposure produces consistent developmental alterations in dopamine-rich regions of the cerebral cortex. Neuroscience. 2001;106:5–14
  10. Stanwood GD, Levitt P. Repeated i.v. cocaine exposure produces long-lasting behavioral sensitization in pregnant adults, but behavioral tolerance in their offspring. Neuroscience. 2003;122:579–583
  11. Jones LB, Stanwood GD, Reinoso BS, et al. In utero cocaine-induced dysfunction of dopamine D1 receptor signaling and abnormal differentiation of cerebral cortical neurons. J Neurosci. 2000;20:4606–4614
  12. Stanwood GD, Levitt P. Prenatal exposure to cocaine produces unique developmental and long-term adaptive changes in dopamine D1 receptor activity and subcellular distribution. J Neurosci. 2007;27:152–157
  13. NIH Consensus Statement. Antenatal corticosteroids revisited: Repeat courses. NIH Consens Statement 2000 August 17-18;17:1-10.
  14. Brocklehurst P, Gates S, McKenzie-McHarg K, Alfirevic Z, Chamberlain G. Are we prescribing multiple courses of antenatal corticosteroids? (A survey of practice in the UK). Br J Obstet Gynaecol. 1999;106:977–979
  15. McCabe L, Marash D, Li A, Matthews SG. Repeated antenatal glucocorticoid treatment decreases hypothalamic corticotropin releasing hormone mRNA but not corticosteroid receptor mRNA expression in the fetal guinea-pig brain. J Neuroendocrinol. 2001;13:425–431
  16. Liu L, Li A, Matthews SG. Maternal glucocorticoid treatment programs HPA regulation in adult offspring: Sex specific effects. Am J Physiol Endocrinol Metab. 2001;280:E729–E739
  17. Owen D, Matthews SG. Repeated maternal glucocorticoid treatment affects activity and hippocampal NMDA receptor expression in juvenile guinea pigs. J Physiol (Lond). 2007;578:249–257
  18. Kapoor A, Matthews SG. Short periods of prenatal stress affects growth, behavior and hypothalamo-pituitary-adrenal axis activity in male guinea pig offspring. J Physiol (Lond). 2005;566:967–977
  19. Griffin MG, Resick PA, Yehuda R. Enhanced cortisol suppression following dexamethasone administration in domestic violence survivors. Am J Psychiatry. 2005;162:1192–1199
  20. Yehuda R, Blair W, Labinsky E, Bierer LM. Effects of parental PTSD on the cortical response to dexamethasone administration in their adult offspring. Am J Psychiatry. 2007;164:163–166
  21. Elbert T, Pantev C, Wienbruch C, Rockstroh B, Taub E. Increased cortical representation of the fingers of the left hand in string players. Science. 1995;270:305–307
  22. Huttenlocher PR, de Courten C, Garey LJ, Van der Loos H. Synaptogenesis in human visual cortex—Evidence for synapse elimination during normal development. Neurosci Lett. 1982;33:247–252
  23. Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol. 1987;22:487–497
  24. Huttenlocher PR, Dabholkar AS. Regional differences in synaptogenesis in human cerebral cortex. Comp Neurol. 1997;387:167–178
  25. Shaw P, Greenstein D, Lerch J, et al. Intellectual ability and cortical development in children and adolescents. Nature. 2006;440:676–679
  26. Cohen-Cory S. The developing synapse: Construction and modulation of synaptic structures and circuits. Science. 2002;298:770–776
  27. Kovalchuk Y, Hanse E, Kafitz KW, Konnerth A. Postsynaptic induction of BDNF-mediated long-term potentiation. Science. 2002;295:1729–1734
  28. Manabe T. Does BDNF have pre- or postsynaptic targets?. Science. 2002;295:1651–1653
  29. Levenson JM, O’Riordan KJ, Brown KD, Trinh MA, Molfese DL, Sweatt JD. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem. 2004;279:40545–40559
  30. Huber KM, Gallagher SM, Warren St, Bear M. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci USA. 2002;99:7746–7750
  31. Szatmari P, Paterson AD, et al. Autism Genome Project Consortium Mapping autism risk loci using genetic linkage and chromosomal rearrangements. Nat Genet. 2007;39:319–328
  32. Jamain S, Quach H, Betancur C, et al. Mutations of the X-linked genes encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat Genet. 2003;34:27–29
  33. Collins AL, Ma D, Whitehead PL, et al. Investigation of autism and GABA receptor subunit genes in multiple ethnic groups. Neurogenetics. 2006;7:167–174
  34. Magistretti PJ, Pellerin L, Rothman DL, Shulman RG. Energy on demand. Science. 1999;283:496–497
  35. Ikonomidou C, Bittigau P, Ishimaru MJ, et al. Ethanol-induced apoptotic neurodegeneration and fetal alcohol syndrome. Science. 2000;287:1056–1060
  36. Slotkin TA. Guidelines for developmental neurotoxicity and their impact on organophosphate pesticides: A personal view from an academic perspective. Neurotoxicology. 2004;25:631–640
  37. Slotkin TA. Cholinergic systems in brain development and disruption by neurotoxicants: Nicotine, environmental tobacco smoke, organophosphates. Toxicol Appl Pharmacol. 2004;198:132–151
  38. Slotkin TA. Developmental neurotoxicity of organophosphates: A case study of chlorpyrifos. In:  Gupta RC editors. Toxicity of organophosphate and carbamate pesticides. San Diego: Elsevier Academic Press; 2005;p. 293–314
  39. Colborn T. A case for revisiting the safety of pesticides: A closer look at neurodevelopment. Environ Health Perspect. 2006;114:10–17
  40. Costa LG. Current issues in organophosphate toxicology. Clin Chim Acta. 2006;366:1–13
  41. Slotkiin TA, Brown KK, Seidler FJ. Developmental exposure of rats to chlorpyrifos elicits sex-selective hyperlipidemia and hyperinsulinemia in adulthood. Environ Health Perspect. 2005;113:1291–1294
  42. Rauh VA, Garfinkel R, Perera R, et al. Impact of prenatal chlorpyrifos exposure on neurodevelopment in the first 3 years of life among inner-city children. Pediatrics. 2006;118:1845–1859
  43. Berkowitz GS, Wetmur JG, Birman-Deych E, et al. In utero pesticide exposure, maternal paraoxonase activity, and head circumference. Environ Health Perspect. 2004;112:388–391
  44. Beer A, Slotkin TA, Seidler FJ, Aldridge JE, Yanai J. Nicotine therapy in adulthood reverses the synaptic and behavioral deficits elicited by prenatal exposure to phenobarbital. Neuropsychopharmacology. 2005;30:156–165
  45. Kinney HC. The near-term (late preterm) human brain and risk for periventricular leukomalacia: A review. Semin Perinatol. 2006;30:81–88
  46. Haynes RL, Folkerth RD, Keefe RJ, et al. Nitrosative and oxidative injury to premyelinating oligodendrocytes in periventricular leukomalacia. J Neuropathol Exp Neurol. 2003;62:441–450
  47. Folkerth RD, Haynes RL, Borenstein NS, et al. Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J Neuropathol Exp Neurol. 2004;63:990–999
  48. Billiards SS, Haynes RL, Folkerth RD, et al. Development of microglia in the cerebral white matter of the human fetus and infant. J Comp Neurol. 2006;497:199–208
  49. Deng W, Rosenberg PA, Volpe JJ, Jensen FE. Calcium-permeable AMPA/kainite receptors mediate toxicity and preconditioning by oxygen-glucose deprivation in oligodendrocyte precursors. Proc Natl Acad Sci USA. 2003;100:6801–6806
  50. Desilva TM, Kinney HC, Borenstein NS, et al. The glutamate transporter EAAT2 is transiently expressed in developing human white matter. J Comp Neurol. 2007;501:879–890
  51. Haynes RL, Baud O, Li J, Kinney HC, Volpe JJ, Folkerth DR. Oxidative and nitrative injury in periventricular leukomalacia: A review. Brain Pathol. 2005;15:225–233
  52. Johnson WG. Teratogenic alleles and neurodevelopmental disorders. Bioessays. 2003;25:464–477
  53. Doolin MT, Barbaux S, McDonnell M, Hoess K, Whitehead AS, Mitchell LE. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. Am J Hum Genet. 2002;71:1222–1226
  54. Williams TA, Mars AE, Buyske SG, et al. Risk of autistic disorder in affected offspring of mothers with a glutathione S-transferase P1 haplotype. Arch Pediatr Adolesc Med. 2007;161:356–361
  55. Zimmerman AW, Connors SL, Pardo-Villamizar CA. Neuroimmunology and neurotransmitters in autism. In:  Tuchman R,  Rapin I editor. Autism: A neurological disorder of early brain development. London: MacKeith Press; 2006;p. 141–159
  56. Slotkin TA, Lau C, Seidler FJ. Beta-adrenergic overexpression in the fetal rat: Distribution, receptor subtypes, and coupling to adenylate cyclase activity via G-proteins. Toxicol Appl Pharmacol. 1994;129:223–234
  57. Duncan CP, Seidler FJ, Lappi SE, Slotkin TA. Dual control of DNA synthesis by alpha- and beta-adrenergic mechanisms in normoxic and hypoxic neonatal rat brain. Brain Res Dev Brain Res. 1990;55:29–33
  58. Crespo P, Cachero TG, Xu N, Gutkind JS. Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase (Evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition). J Biol Chem. 1995;270:25259–25265
  59. Schmitt JM, Stork PJ. Beta 2-adrenergic receptor activates extracellular signal-related kinases (ERKs) via the small G protein rap1 and the serine/threonine kinase B-Raf. J Biol Chem. 2000;275:25342–25350
  60. Kwon JH, Eves EM, Farrell S, et al. Beta-adrenergic receptor activation promotes process outgrowth in an embryonic rat basal forebrain cell line and in primary neurons. Eur J Neurosci. 1996;8:2042–2055
  61. Gu C, Ma YC, Benjamin J, Littman D, Chao MV, Huang XY. Apoptotic signalling through the beta-adrenergic receptor (A new Gs effector pathway). J Biol Chem. 2000;275:20726–20733
  62. Gharami K, Das S. Thyroid hormone-induced morphological differentiation and maturation of astrocytes are mediated through the beta-adrenergic receptor. J Neurochem. 2000;75:1962–1969
  63. Zhu WZ, Zheng M, Koch WJ, Lefkowitz RJ, Kobilka BK, Xiao RP. Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci USA. 2001;98:1607–1612
  64. Bauman ML, Kemper TL. Neuroanatomic observations of the brain in autism: A review and future directions. Int J Dev Neurosci. 2005;23:183–187
  65. Casanova MF, van Kooten IA, Switala AE, et al. Minicolumnar abnormalities in autism. Acta Neuropathol (Berl). 2006;112:287–303
  66. Vargas DL, Nascimbene C, Krishnan C, Zimmerman AW, Pardo C. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol. 2005;57:67–81
  67. Rhodes MC, Seidler FJ, Abdel-Rahman A, et al. Terbutaline is a neurotoxicant: Effects on neuroproteins and morphology in cerebellum, hippocampus, and somatosensory cortex. J Pharmacol Exp Ther. 2004;308:529–537
  68. Zerrate MC, Pletnikov M, Connors SL, et al. Neuroinflammation and behavioral abnormalities after neonatal terbutaline treatment in rats: Implications for autism. J Pharmacol Exp Ther. 2007;322:16–22
  69. Lam F, Elliott J, Jones JS, et al. Clinical issues surrounding the use of terbutaline sulfate for preterm labor. Obstet Gynecol Surv. 1998;53(Suppl. 11):S85–S95
  70. Bergman B, Bokstrom H, Borga O, Enk L, Hedner T, Wangberg B. Transfer of terbutaline across the human placenta in late pregnancy. Eur J Respir Dis. 1984;134(Suppl):81–86
  71. Hsu CH, Robinson CP, Basmadjian GP. Tissue distribution of 3H-terbutaline in rabbits. Life Sci. 1994;54:1465–1469
  72. Connors SL, Crowell DE, Eberhart CG, et al. Beta2-adrenergic receptor activation and genetic polymorphisms in autism: Data from dizygotic twins. J Child Neurol. 2005;20:876–884
  73. Liggett SB. Polymorphisms of the beta2-adrenergic receptor. N Engl J Med. 2002;346:536–538
  74. Dishy V, Sofowora GG, Xie HG, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med. 2001;345:1030–1035
  75. Cheslack-Postava K, Fallin MD, Avramopoulos D, et al. Beta2-adrenergic receptor gene variants and risk for autism in the AGRE Cohort. Mol Psychiatry. 2007;12:283–291
  76. Hadders-Algra M, Touwen BCL, Huisjes HJ. Long-term follow-up of children prenatally exposed to ritodrine. Br J Obstet Gynaecol. 1986;93:156–161
  77. Pitzer M, Schmidt MH, Esser G, Laucht M. Child development after maternal tocolysis with beta-sympathomimetic drugs. Child Psychiatry Hum Dev. 2001;31:165–182
  78. Beversdorf DQ, Manning SE, Hillier A, et al. Timing of prenatal stressors and autism. J Autism Dev Disord. 2005;35:471–478

PII: S0887-8994(07)00542-5

doi: 10.1016/j.pediatrneurol.2007.10.009

Pediatric Neurology
Volume 38, Issue 3 , Pages 163-176 , March 2008

Article Tools